Six early-stage companies, including two life science companies, were announced winners Wednesday in the Arizona Commerce Authority’s Spring 2014 Arizona Innovation Challenge.Continue reading
Author Archive: AZBio
Managing specialized microbes to clean stubborn chemicals from the environment
Chlorinated chemicals perform a host of societally useful functions, but they also have a dark side. Once their use life has ended, such agents often become environmental contaminants, sometimes resistant to bioremediation.Continue reading
InVivo Therapeutics announces second Arizona Based Clinical Trial Site
InVivo Therapeutics Announces Barrow Neurological Institute As Third Clinical Trial Site for Neuro-Spinal ScaffoldContinue reading
BIO BizLink streamlines CROs, CMOs and regulatory consultant search and evaluation
Merz to Acquire Ulthera for $600M
MERZ TO ACQUIRE ULTHERA, INC., A LEADING ENERGY DEVICE COMPANY IN THE AREA OF NON-SURGICAL LIFTContinue reading
2014 Life Sciences Workforce Trends Report Released at BIO.
The Coalition of State Bioscience Institutes (CSBI) Releases the 2014 Life Sciences Workforce Trends Report at BIO. Key Findings Support Industry Hiring Demand with a Strong Need for Knowledge‐Based Employees.
Calimmune (Tucson, AZ) Approved to Treat Second Group in HIV Stem Cell Gene Modification Study
June 25, 2014
San Diego, CA – Calimmune today announced encouraging safety data from its innovative gene-based stem cell therapy, Cal-1-being developed to help cure individuals infected with HIV. The company can now begin treating the second group of patients in the trial, which is being funded in part by a grant from the California Institute for Regenerative Medicine (CIRM).Continue reading
Insys Therapeutics Receives FDA Orphan Drug Designation for Its Pharmaceutical Cannabidiol as a Potential Treatment for Rare Form of Epilepsy, Lennox-Gastaut Syndrome
Insys Therapeutics, Inc. (INSY), a specialty pharmaceutical company that is developing and commercializing innovative drugs and novel drug delivery systems, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to its pharmaceutical cannabidiol (CBD) for the treatment of Lennox-Gastaut Syndrome, a rare pediatric-onset epilepsy.Continue reading
Battelle/BIO Release State Bioscience Jobs, Investments and Innovation 2014 Report
Battelle/BIO State Bioscience Jobs, Investments and Innovation 2014:
A Robust Bioscience Industry with Strong Prospects for GrowthContinue reading